Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

Inclusion Criteria: * Able to understand and voluntarily provide written informed consent prior to initiation of any study-specific procedures * Male or female, age ≥ 18 years * Scheduled to undergo unilateral, uncomplicated intravitreal injection of an FDA-approved, non-biosimilar anti-VEGF agent in the study eye * Diagnosis requiring anti-vascular endothelial growth factor (anti-VEGF) treatment, including macular edema (cystoid or diabetic), retinal vein occlusion, diabetic retinopathy, or neovascular age-related macular degeneration * At least three prior intravitreal anti-VEGF injections in the study eye * Fewer than 13 intravitreal anti-VEGF injections in the study eye within the last 365 days * Willing and able to comply with study procedures and follow-up assessments Exclusion Criteria: * Scheduled to undergo simultaneous bilateral intravitreal injection * Pre-existing eye pain in the study eye * Fewer than three prior intravitreal anti-VEGF injections in the study eye within 365 days prior to enrollment * Mental disability or cognitive impairment that prevents reliable pain assessment * Prisoner * Pregnant or breastfeeding * Woman of childbearing potential not using an acceptable method of contraception * Inability to comply with study procedures or follow-up assessments * Known sensitivity or allergy to any study medications or related drug classes * History of resistance to local anesthetics * History of Ehlers-Danlos syndrome * Participation in another investiga…